Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
XY Therapeutics logo — Developing a novel first-in-class treatment for male inferti...

XY Therapeutics

Developing a novel first-in-class treatment for male infertility.

Founded 2020 Denmark Denmark 3 employees Biopharma, Biotechnology +1

General Information

Company Name XY Therapeutics
Founded Year 2020
Location Denmark Denmark +1
Founders / Decision Makers
Team member
Employees 3
Industries Biopharma, Biotechnology, Health and Wellness
Social

Get notified when XY Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About XY Therapeutics

XY Therapeutics is a biopharmaceutical startup that focuses on developing a novel first-in-class treatment for male infertility. Based on over 10 years of research from Kingdom Hospital in Copenhagen, Denmark, the company is dedicated to addressing the unmet medical need for infertile couples. Their proprietary treatment, which has shown promising results in preclinical and clinical studies, targets the RANKL/RANK/OPG pathway in the reproductive organs and has the potential to increase sperm production and function. One of the notable aspects of XY Therapeutics' approach is the identification and patenting of a biomarker that can select the men who will benefit from the treatment. This biomarker is being developed into a companion diagnostic, which could significantly impact the way clinicians and fertility experts select appropriate candidates for the therapy. Currently, XY Therapeutics' treatment is undergoing Phase 2A trials, and a successful outcome could represent a crucial breakthrough in a field where treatment options for male infertility are limited. The potential impact of their innovation is far-reaching, affecting not only the individuals suffering from infertility but also society and the economy. XY Therapeutics has the potential to make a significant contribution to the biopharma, biotechnology, and health and wellness industries. With their innovative approach and promising results, the company stands as an intriguing opportunity for venture capital investors seeking to support groundbreaking solutions in the field of reproductive medicine. For more information, visit xytherapeutics.dk.

Taxonomy: Male Infertility, Medical Treatment, Reproductive Medicine, Clinical Trials, Companion Diagnostics, Biomarker Development, Research and Development, Innovation, Sperm Function, Therapeutic Development, Fertility Solutions

No funding data available for XY Therapeutics yet.

Get notified when XY Therapeutics raises funding

XY Therapeutics Alternatives & Competitors

XY Therapeutics vs
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. United States

Daring to create a world immune to cancer.

Post Ipo Equity
18 employees
Biotechnology, Health and Wellness
XY Therapeutics vs
Palatin Technologies
Palatin Technologies

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune cond...

Post Ipo Equity
50 employees
Biotechnology, Health Care
XY Therapeutics vs
Vyome Holdings, Inc.
Vyome Holdings, Inc. United States

Vyome is building the world’s premier biotech, AI-healthcare platform spanning the US-India innovati...

IPO
19 employees
Biotechnology, Health Care

FAQ About XY Therapeutics

Developing a novel first-in-class treatment for male infertility.
XY Therapeutics was founded in 2020.
XY Therapeutics is headquartered in Denmark.
XY Therapeutics operates in the following industries: Biopharma, Biotechnology, Health and Wellness.
XY Therapeutics has approximately 3 employees.
Top alternatives and competitors to XY Therapeutics include Jounce Therapeutics, Inc., Palatin Technologies, Vyome Holdings, Inc., CHORD Therapeutics, Humed Technologies, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
XY Therapeutics and Jounce Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors XY Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy